Ruxolitinib is an oral small-molecule inhibitor of Janus kinase (JAK) 1 and JAK2, developed to target abnormal JAK-STAT signaling involved in certain blood disorders and inflammatory diseases. It was discovered and developed by Incyte and later partnered with Novartis for broader commercialization. Ruxolitinib became the first JAK inhibitor approved by the U.S. Food and Drug Administration in 2011 for the treatment of myelofibrosis, marking a major advancement in targeted therapy for myeloproliferative neoplasms. It was later approved for polycythemia vera and graft-versus-host disease, and topical formulations have also been developed for certain inflammatory skin conditions.
Image
